Neurol. praxi. 2011;12(6):403-406

The use of monoclonal antibodies in neurology

prof.MUDr.Egon Kurča, PhD., MUDr.Mária Cuninková
Neurologická klinika JLF UK a Univerzitnej nemocnice, Martin

Monoclonal antibodies currently represent one of the highest stages of pharmacological development. In contrast to previous opinions,

it seems that they will be applied not only to treat autoimmune diseases, but their real clinical use will obviously be broader including,

for example, tumour-related problems. The review article provides current information on the real and potential use of monoclonal

antibodies in neurological diseases.

Keywords: monoclonal antibodies, treatment of neurological diseases, multiple sclerosis

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kurča E, Cuninková M. The use of monoclonal antibodies in neurology. Neurol. praxi. 2011;12(6):403-406.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009; 66(4): 483-489. Go to original source... Go to PubMed...
    2. Buie LW, Valgus J. Bevacizumab: a treatment option for recurrent glioblastoma multiforme. Ann Pharmacother 2008; 42(10): 1486-1490. Go to original source... Go to PubMed...
    3. CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359(17): 1786-1801.
    4. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: posthoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011; 10(4): 338-348. Go to original source... Go to PubMed...
    5. Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, Shrader JA, Levy EW, Dambrosia J, Kampen RL, Bruno DA, Kirk AD. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009; 132(6): 1536-1544. Go to original source... Go to PubMed...
    6. Glassy MC, Hagiwara H. Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab. Hum Antibodies 2009; 18(4): 127-137. Go to original source... Go to PubMed...
    7. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sörensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 2010; 12(5): 508-16.
    8. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358(7): 676-688. Go to original source... Go to PubMed...
    9. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH; OLYMPUS trial group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66(4): 460-471. Go to original source... Go to PubMed...
    10. Panza F, Frisardi V, Imbimbo BP, Seripa D, Paris F, Santamato A, D'Onofrio G, Logroscino G, Pilotto A, Solfrizzi V. Anti-?-Amyloid Immunotherapy for Alzheimer's Disease: Focus on Bapineuzumab. Curr Alzheimer Res 2011. [Epub ahead of print]. Go to original source... Go to PubMed...
    11. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 899-910. Go to original source... Go to PubMed...
    12. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH; Ustekinumab MS Investigators. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008; 7(9): 796-804. Go to original source... Go to PubMed...
    13. Rios Fernández R, Callejas Rubio JL, Sánchez Cano D, Sáez Moreno JA, Ortego Centeno N. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 2009; 27(6): 1009-1016. Go to PubMed...
    14. Samadi H, Sultzer D. Solanezumab for Alzheimer's disease. Expert Opin Biol Ther 2011; 11(6): 787-798. Go to original source... Go to PubMed...
    15. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 911-923. Go to original source... Go to PubMed...
    16. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, Berthold F. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 2011; 11: 21. Go to original source... Go to PubMed...
    17. Thompson B, Corris P, Miller JA, Cooper RG, Halsey JP, Isaacs JD. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol 2008; 35(10): 2080-2082. Go to PubMed...
    18. Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI, Eagle M, Florence JM, King WM, Pandya S, Straub V, Juneau P, Meyers K, Csimma C, Araujo T, Allen R, Parsons SA, Wozney JM, Lavallie ER, Mendell JR. A phase I/IItrial of MYO029 in adult subjects with muscular dystrophy. Ann Neurol 2008; 63(5): 561-571. Go to original source... Go to PubMed...
    19. Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil SS, Gold R, Hemmer B, Kieseier BC, Stüve O. Natalizumab and Progressive Multifocal Leukoencephalopathy. What Are the Causal Factors and Can It Be Avoided? Arch Neurol 2010; 67(8): 923-930. Go to original source... Go to PubMed...
    20. Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW. CHOICE investigators. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, doubleblind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9(4): 381-90. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.